This article is available online at http://www.jlr.org Health consequences associated with low intakes of the long-chain, marine omega-3 (n3) FAs have become a central issue in nutritional lipid research. The United States Department of Agriculture's 2010 Dietary Guidelines recommend consumption of 8 ounces per week of fi sh, providing an average of 250 mg eicosapentaenoic acid (20:5n3) and docosahexaenoic acid (22:6n3) per day for prevention of heart disease ( 1 ). Moreover, public awareness regarding the potential health benefi ts of n3 FAs has spurred an increase in fatty fi sh and fi sh oil consumption ( 2 ).Although the mechanisms by which n3-HUFAs improve health are still being explored, it is clear that increasing n3-HUFA intake can decrease the risk of cardiovascular disease (CVD) in at-risk individuals ( 3-5 ). In hyperlipidemic subjects, treatment with high doses of n3-HUFAs lowers triglycerides ( 6 ) and improves total:HDL cholesterol ratios ( 6, 7 ), a surrogate marker associated with a reduction in CVD risk. The n3-HUFAs 20:5n3 and 22:6n3 also reduce infl ammatory responses in a range of conditions ( 8-10 ). A well-accepted effect of n3-HUFA supplementation is a reduction in thrombin-stimulated platelet aggregation due to decreased platelet cyclooxygenase metabolism ( 11 ). More recently, a cyclooxygenase-independent diminution of platelet sensitivity to collagen has been reported after P-OM3 treatment ( 12 ). Thus, an increase in the anti-infl ammatory n3-HUFAs, which lowers the more proinfl ammatory n6-HUFAs ( 13-15 ), at least partially explains the health benefi ts of n3-HUFA consumption ( 8-10 ). 5306-51530-019-00D (J.W.N.), National Institute of Food and Agriculture National Needs Fellowship grant 2008-38420-04759 (A.H.K.), and by grant LVZ112860 from GlaxoSmithKline (G.C.S.) Abbreviations: CVD, cardiovascular disease; HUFA, highly unsaturated fatty acid; P-OM3, prescription omega-3 acid ethyl esters; RBC, red blood cell.